Atossa Therapeutics
ATOS
$1.54
Share price
5.48%
Change (1 day)
116.90%
Change (1 year)
Categories
Atossa Therapeutics (ATOS) - Cash on Hand
Cash on Hand as of September 2023 : $94.03 M
According to Atossa Therapeutics's latest financial reports the company has $94.03 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Atossa Therapeutics - Cash on Hand chart (from 2010 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.11 B | -18.69% |
| 2021-12-31 | $0.13 B | 244.79% |
| 2020-12-31 | $39.55 M | 214.39% |
| 2019-12-31 | $12.58 M | 21.2% |
| 2018-12-31 | $10.38 M | 43.82% |
| 2017-12-31 | $7.21 M | 138.36% |
| 2016-12-31 | $3.02 M | -18.51% |
| 2015-12-31 | $3.71 M | -56.29% |
| 2014-12-31 | $8.5 M | 34.04% |
| 2013-12-31 | $6.34 M | 267.62% |
| 2012-12-31 | $1.72 M | -9.71% |
| 2011-12-31 | $1.91 M | 18536.7% |
| 2010-12-31 | $0.01 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $26.21 B | 27,782.29% | 🇺🇸 USA |
 Quest Diagnostics
DGX | $0.47 B | 404.09% | 🇺🇸 USA |
 LabCorp LH | $99.3 M | 5.60% | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | N/A | N/A | 🇺🇸 USA |
 NeoGenomics
NEO | $0.38 B | 309.26% | 🇺🇸 USA |
 Enzo Biochem ENZ | $60.24 M | -35.93% | 🇺🇸 USA |